BACKGROUND: The prevalence of irritable bowel syndrome with constipation (IBS-C) is estimated to be between 4.3% and 5.2% among adults in the United States. Little is known about the health care resource utilization and costs associated with IBS-C.
RESULTS: A total of 7,652 patients (n = 3,826 each in the IBS-C and control cohorts) were included in the analysis. The mean (± SD) age was 48 (± 17) years, and 83.6% were female. The mean annual all-cause health care costs for IBS-C patients were $11,182, with over half (53.7%) of the costs attributable to outpatient services, including physician office visits and other outpatient services (13.1% and 40.6%, respectively). Remaining total all-cause costs were attributable to hospitalizations (21.8%), prescriptions (19.1%), and ER visits (5.4%). GI-related costs ($4,456) comprised 39.8% of total all-cause costs, while IBS-C-related costs ($1,335) accounted for 11.9% and were primarily driven by costs of other outpatient services
R E S E A R C H
• Previous studies have demonstrated that patients with irritable bowel syndrome with constipation (IBS-C) represent a substantial economic burden to both managed care and employers. • The total cost difference for IBS patients compared with matched controls has been estimated at $1,896 (in 2010 U.S. dollars) among patients in a health maintenance organization (HMO) and $1,674 (in 2010 U.S. dollars) for patients identified from a U.S. employer database.
• There is a paucity of data on health care costs specific to IBS-C, with very few existing studies reporting direct costs specifically for IBS-C.
What is already known about this subject
• This study evaluated the economic burden associated with IBS-C among patients in a commercially insured population using 2 cost of illness approaches: the total cost approach, which assessed the sum of all-cause or disease-specific health care costs for patients with IBS-C, and the incremental cost approach, which estimated the excess all-cause costs attributable solely to the presence of IBS-C by comparing IBS-C patients with matched controls. Together, these 2 approaches provided a more thorough assessment of IBS-C cost of illness.
• Rigorous exploratory analyses were conducted to determine the most appropriate and reliable inclusion and exclusion criteria to identify IBS-C patients based on medical and pharmacy claims.
which do not reflect actual costs of health care resources used to deliver care. This study only required 1 medical claim with a diagnosis of IBS and 1 medical claim of constipation occurring any time during the 3-year study period to identify IBS-C patients, which may have resulted in misclassification bias, since it permitted inclusion of patients with an isolated incident of constipation rather than chronic constipation. This study also used an incidence-based approach to assess burden of illness, which tends to reflect the average cost of illness during the peri-diagnostic period. For chronic conditions, such as IBS-C, a prevalence-based approach may be more suitable for informing payers of the total economic burden of disease, since it characterizes the average annual cost per patient for all patients with the disease within a given time frame. 12 Another study assessing the impact of IBS-C based on the 2007 U.S. National Health and Wellness Survey found that IBS-C patients reported greater health care resource utilization than matched controls, 13 but this study did not extend assessment to health care costs, and identification of IBS-C patients was based on self-reported survey data.
Because evidence-based data specific to the economic burden of IBS-C are limited, the purpose of this study was to conduct a prevalence-based cost-of-illness analysis for IBS-C from a commercial payer perspective. Specifically, this study used the total cost approach to estimate the total annual allcause, GI-related, and IBS-C-related health care costs among IBS-C patients seeking medical care and the incremental cost approach to estimate the incremental annual all-cause health care costs of IBS-C patients relative to matched controls.
■■ Methods Data Source
Medical, pharmacy, and eligibility claims data were extracted from the HealthCore Integrated Research Database (HIRD), which consists of administrative claims data of patients from 14 geographically dispersed U.S. health plans representing 44 million lives. The HIRD is one of the largest datasets of a commercially insured U.S. population. Overall, demographic characteristics of the HIRD population are generally comparable with the U.S. Census data (American Community Survey) by age and gender. However, since commercial insurance typically consists of working individuals and their dependents, the HIRD population tends to be slightly younger, and individuals over 65 years of age tend to be underrepresented.
All personally identifiable data used in this observational study were de-identified and accessed with protocols compliant with the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). Patient confidentiality was preserved, and the anonymity of all patient data was safeguarded throughout the study. No waiver of informed consent was required from an institutional review board. I rritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder characterized by abdominal pain or discomfort associated with altered bowel habits.
1 IBS is most often diagnosed by gastroenterologists, and symptoms of IBS are among the top 10 reasons patients visit their primary care physicians.
2 The Rome III diagnostic criteria, developed by the Rome Foundation, are considered the current gold standard for diagnosing IBS patients and characterizing them into symptom-based subtypes, including IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and IBS with mixed bowel patterns (IBS-M) of both constipation and diarrhea. According to the Rome III criteria, IBS is defined as recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with 2 or more of the following: (1) improvement with defecation, (2) onset associated with a change in stool frequency, and/or (3) onset associated with a change in stool form.
3 IBS-C patients are classified as having hard or lumpy stools for ≥ 25% of bowel movements and loose or watery stools for < 25% of bowel movements in the absence of antidiarrheal or laxative use.
3 IBS-C is estimated to affect 4.3% to 5.2% of the adult population in the United States, 4-6 with prevalence estimates varying due to differences in the criteria (including Manning, Rome I, and Rome II) used to define IBS-C patient populations across existing studies. While prior studies have examined the substantial economic impact of IBS, these studies have only focused on overall IBS, not IBS subtypes 7, 8 and have often assessed health care charges rather than costs. 9, 10 Reported direct cost estimates for IBS range from $1,674 (2010 U.S. dollars [USD]) 8 to $1,896 (2010 USD) 7 per patient per year. Given the different symptomatology associated with the subtypes of IBS, health care costs of IBS-C may differ from those estimated for overall IBS and other IBS subtypes. One recent study specific to IBS-C patients estimated incremental charges to be $5,441 (in 2010 USD) higher for IBS-C patients than for age-and gender-matched controls in a managed care population. 11 However, similar to studies among IBS patients, 9, 10 this study estimated health care charges as opposed to costs,
• IBS-C patients incurred significantly higher total annual all-cause costs that were nearly double that of matched controls, with an incremental difference of $3,856 (in 2010 U.S. dollars) per patient per year after adjusting for demographic characteristics and potential confounding effects of general and gastrointestinalrelated comorbidities.
• Incremental annual all-cause costs associated with IBS-C were mainly driven by costs related to more frequent use of medical services, which accounted for 78% of incremental all-cause costs. 
What this study adds (continued)

Study Design
This study was a retrospective administrative claims database analysis in a commercially insured population in the United States. Two cost of illness approaches were used to estimate the costs of IBS-C: the total cost approach, which assessed the sum of all-cause or disease-specific health care costs for patients with IBS-C, and the incremental cost approach, which estimated the excess all-cause costs attributable solely to the presence of IBS-C by comparing IBS-C patients with matched controls. 14 Together, these 2 approaches provided a more thorough assessment of the cost of illness of IBS-C. Since IBS-C is a chronic condition, with patients often experiencing symptoms over long periods of time, a prevalence-based approach was used to estimate the economic burden of illness from a payer perspective. 12 A 1-year time frame for claims eligibility was selected to assess the annual costs of IBS-C. The study period was defined as January 1, 2010, through December 31, 2010, based on the most recent calendar-year data available at the time this study was conducted.
Study Population
Patients aged 18 years or older with 12 months of continuous medical and pharmacy benefits for the 2010 calendar year were selected for analysis. Considering the limitations of administrative claims database analyses, including the lack of an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code for IBS-C and the inconsistent use of existing ICD-9-CM diagnosis codes for IBS and constipation due to over-and undercoding of these symptoms, detailed exploratory analyses were conducted to refine the patient identification criteria and mitigate the risk of misclassification. These exploratory analyses were conducted prior to finalization of the study protocol and execution of analyses of costs in IBS-C patients and controls and were guided by advice from gastroenterologists regarding the selection of potential inclusion and exclusion criteria. The impact of these criteria on the sample size of the study population was evaluated based on descriptive analyses assessing the number of patients with at least 1 versus 2 medical claims for IBS, constipation, and other GI conditions and the number of patients with pharmacy claims for constipationrelated prescriptions (e.g., lubiprostone, stimulant laxatives, or osmotic laxatives). Additionally, the number of days between medical and/or pharmacy claims for IBS, constipation, and constipation-related prescriptions was evaluated to determine whether and what defined time-window between claims events would be appropriate to reliably identify patients with IBS-C. Gastroenterologists were consulted to evaluate and approve the final inclusion and exclusion criteria.
Based on results of the exploratory analyses and clinical opinion, patients were classified as having IBS-C if they met the following criteria: (a) ≥ 1 medical claim with an ICD-9-CM diagnosis code in any position for IBS (ICD-9-CM 564.1x) in 2010 and (b) ≥ 2 medical claims for constipation (ICD-9-CM 564.0x) on different dates of service in 2010 or ≥ 1 medical claim for constipation plus ≥ 1 pharmacy claim for a constipation-related prescription, including lubiprostone, stimulant laxatives, osmotic laxatives, or stool softeners, on different dates of service in 2010.
To avoid inclusion of patients with IBS-D, IBS-M, chronic diarrhea, drug-induced constipation, or other GI conditions or medications that may affect GI system function, exclusion criteria were defined and applied based on a review of previous studies, 8, 11 clinical opinion, and results of the exploratory analyses. Patients were also excluded if they had 1 or more medical claims for any conditions that may be misdiagnosed as IBS-C (e.g., GI malignancy, Crohn's disease, ulcerative colitis, celiac disease, vascular insufficiency of intestine, intestinal malabsorption, diverticulitis) or that may present with similar symptoms to IBS-C (e.g., multiple sclerosis, Parkinson's disease, diabetic neuropathy, pancreatitis; see Figure 1 for exclusion criteria).
To estimate the incremental costs attributable to IBS-C, controls were randomly selected and matched with IBS-C patients in a 1:1 ratio based on age (± 4 years); gender; health plan region (Northeast, South, Midwest, and West); and health plan type Matching on health plan region and health plan type was conducted to control for differences in regional practice patterns and health plans that may confound estimates of the incremental health care costs of IBS-C patients versus controls. For a few cases, wherein a matched control could not be identified from the same type of health plan within the same region, the control was identified within the same region but from a similar health plan type based on a predetermined category of health plan types (i.e., PPO, HMO, consumer driven health plan such as HRA and HSA, or other health plan types). The exclusion criteria applied to the IBS-C cohort were also applied to potential controls prior to matching. In addition, patients in the control group could not have any medical claims for IBS, constipation, IBS-C-associated symptoms (including abdominal pain and bloating), or pharmacy claims for constipationrelated prescriptions in 2010.
Outcome Measures
Outcome measures were annual health care costs, including all-cause, GI-related, and IBS-C-related costs. All-cause health care costs were defined as the sum of health plan-paid and patient-paid direct health care costs incurred from all medical services and prescription claims associated with any condition during the study period. GI-related health care costs included health plan-paid and patient-paid costs associated with GI-related conditions, including gastroesophageal reflux disease (GERD), esophagitis, dyspepsia, gallbladder or biliary disease, GI hemorrhage, hemorrhoids, IBS, and constipation. These conditions, selected based on clinical consultation and a review of clinically relevant literature, 8, 9, 11 are commonly assessed GI comorbidities among IBS-C patients. IBS-C-related health care costs were defined as health plan-paid and patientpaid costs associated with IBS and constipation.
All-cause medical services were defined as health care resource utilization associated with any condition incurred from inpatient admissions; emergency room (ER) visits; physician office visits; and other outpatient services, including diagnostic tests, outpatient procedures (e.g., endoscopies), laboratory tests, radiology services, and nonpharmacological therapies. All-cause prescription use was calculated as the mean number of standardized monthly all-cause prescription fills derived by dividing the annual days supply of each prescription by 30 days.
Patients' comorbid conditions were measured using the Elixhauser Comorbidity Index (ECI) score, a claims-based measure of overall disease burden based on the occurrence of at least 1 of more than 30 comorbid conditions identified using the ICD-9-CM coding manual. 16 In addition to the ECI, 9 general comorbidities (including insomnia, malaise and fatigue, functional pain disorders, headache, hyperlipidemia, urinary tract infection, anxiety, dysuria, myalgia, and myositis) and 6 GI-related comorbidities (including GERD, esophagitis, dyspepsia, gallbladder or biliary disease, GI hemorrhage, and hemorrhoids) not included in the ECI were also assessed. These additional comorbidities were identified as common comorbid conditions or comorbid consequences of IBS-C, based on clinically relevant literature 8, 9, 11 and expert clinical opinion.
Statistical Analyses
For descriptive analyses, mean, standard deviation (SD), and median were reported for all continuous variables. Frequency and percentages were reported for categorical variables. To compare IBS-C patients and matched controls, McNemar's tests were used for categorical variables such as gender and presence of comorbid conditions, and nonparametric bootstrap estimation and t-tests were used for continuous variables, such as all-cause costs. Generalized linear models (GLMs) were used to assess the incremental all-cause costs attributable to IBS-C after adjusting for demographics, ECI score, and general and GI-related comorbidities not included in the ECI to ensure isolation of incremental costs attributable to IBS-C. Diagnostic tests were conducted to evaluate the distribution of costs, while the modified Park test was used to determine the appropriate family for each of the GLMs. 17 The Pregibon link test, modified Hosmer and Lemeshow test, and Pearson's correlation test were used to select the appropriate link function for each of the GLMs. 18 Adjusted incremental medical and prescription costs were estimated using the method of recycled predictions. 19 Nonparametric bootstrapping was used to assess the statistical significance of these incremental cost estimates.
All costs are reported in 2010 USD. Differences were considered significant if the P value was less than 0.05. All data analyses were conducted using SAS version 9.2 (SAS Inc., Cary, NC) and STATA version 12 (StataCorp LP, College Station, TX).
■■ Results Demographic and Clinical Characteristics
A total of 7,652 patients (n = 3,826 in each cohort) were included in the study (Figure 1) . Overall, the mean age was 48 
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years (± 17 years); 83.6% were female; and 74.9% were covered by a PPO health plan (Table 1) . Patients in the IBS-C cohort had significantly greater morbidity than matched controls as reflected by a higher mean ECI score (1.5 vs. 0.6, P < 0.01). Additionally, the IBS-C cohort had a significantly higher percentage of patients with general and GI-related comorbidities, as well as prescriptions filled, compared with matched controls (Table 1) .
Total Costs of IBS-C
Total annual all-cause health care costs for IBS-C patients were $11,182 (Figure 2 ). More than half (53.7%) of these costs were attributable to physician office visits and other outpatient services (13.1% and 40.6%, respectively). Remaining costs were due to inpatient hospitalizations (21.8%), followed by prescriptions (19.1%) and ER visits (5.4%). Of the total all-cause costs, IBS-C patients incurred $4,456 (39.8%) in costs attributable to GI-related conditions and $1,335 (11.9%) in IBS-C-related costs. Other outpatient services were the primary driver of IBS-C-related costs (50.3%), of which half were for diagnostic tests and outpatient procedures, such as endoscopies.
Incremental Costs of IBS-C
Patients in the IBS-C group incurred $8,066 more in unadjusted total all-cause costs than matched controls (P < 0.01; Figure 3) , with an incremental difference of $6,705 (83.1%) from medical costs and $1,361 (16.7%) from prescription costs. Specifically, IBS-C patients incurred $3,306 (P < 0.01) more in unadjusted costs for other outpatient services; $1,812 (P < 0.01) more in all-cause hospitalization costs; $1,062 (P < 0.01) more in costs for physician office visits; and $525 (P < 0.01) more in costs for ER visits compared with matched controls.
These differences in costs were driven by a higher rate of use of health care services, as well as higher frequency of utilization among users (data not shown). Compared with matched controls, the IBS-C cohort had a significantly higher percentage of patients with hospitalizations (18.1% vs. 5.9%, P < 0.01); ER visits (30.4% vs. 8.3%, P < 0.01); physician office visits (99.7% vs. 73.4%, P < 0.01); other outpatient services (99.2% vs. 69.8%, P < 0.01); and prescription fills (88.6% vs. 62.4%, P < 0.01) for any reason in 2010. Other outpatient services were the primary driver of incremental costs.
After adjusting for demographic characteristics and comorbidities, the incremental all-cause health care costs associated with IBS-C were $3,856 ($8,621 vs. $4,765, P < 0.01; Figure  3) , of which 78.1% was from medical costs ($6,785 vs. $3,773, P < 0.01) and 21.9% was from prescription costs ($1,836 vs. $992, P < 0.01).
■■ Discussion
This study is one of the first to assess direct annual health care costs specific to IBS-C and demonstrate the significant incremental all-cause costs associated with this condition, even after controlling for demographic characteristics and general and GI-related comorbidities. To better identify IBS-C patients seeking medical care and controls, rigorous exploratory analyses were conducted to determine appropriate inclusion and exclusion criteria, and an exact matching method was used for selecting matched controls to ensure that their age, gender, health plan region, and health plan types were as similar as possible to those of IBS-C patients. Two cost of conditions with significant impact on patient health that do not overlap clinically with functional GI disease. Additionally, similar to IBS-C, migraine also disproportionately affects more women than men, with treatment consisting of both prescription and over-the-counter medications. 20 The total annual per patient costs of IBS-C found in this study are comparable with annual costs estimated for migraine patients 21 and comparable or higher than those for patients with asthma, although cost drivers may vary across therapeutic areas. 22, 23 Mitra et al. (2011) 11 also used migraine as a benchmark and found the adjusted 12-month all-cause health care charges for migraine patients to be much lower than those for IBS-C patients. These comparisons indicate IBS-C presents a similar, if not more costly, burden to the health care system compared with other chronic conditions for which there tends to be higher awareness among payers, further emphasizing the need to reduce health care costs associated with IBS-C.
Limitations
The results of this study should be interpreted in light of certain limitations. As with all retrospective claims database analyses, definitive diagnoses are not available, and to our illness approaches were utilized to assess total and incremental costs of IBS-C to thoroughly evaluate the economic burden associated with this condition. Furthermore, an extensive list of evidence-based comorbid conditions was adjusted for in the multivariable models to isolate the incremental costs of IBS-C.
Patients with IBS-C incurred significantly higher adjusted total annual all-cause costs that were nearly double that of matched controls. Incremental costs associated with IBS-C in this study were primarily driven by costs associated with more frequent use of medical services, which accounted for nearly 80% of total all-cause costs. Physician office visits and other outpatient services were the most frequently utilized medical services, with significantly higher average use by patients with IBS-C compared with matched controls. Prescription costs represented a small portion of incremental all-cause costs.
The magnitude of the burden of IBS-C can be put into perspective by comparing it with the economic burden of other chronic conditions, such as migraine and asthma, although such comparisons should be made with caution as methodologies differ across studies, and other studies do not always include all types of costs. Comparisons with migraine and asthma are informative because both are chronic symptomatic A few caveats that may have influenced our incremental cost estimates in either direction also deserve mention. Given the sample inclusion criteria (i.e., ≥ 1 medical claim for IBS and ≥ 2 medical claims for constipation or ≥ 1 medical claim for constipation plus ≥ 1 pharmacy claim for a constipation-related prescription), it is possible IBS-C patients identified in the claims were those seeking more frequent medical care and, hence, may have higher health care costs, resulting in an overestimation of incremental costs in our study. Furthermore, given the chronic and cyclical nature of IBS-C, patients who were previously diagnosed and whose symptoms are under control may not have had claims for IBS or constipation within the study period, in which case the costs for these patients may be lower, and our incremental cost estimates may be overestimated. At the same time, to the extent that we fail to capture patients who were undercoded for constipation (e.g., once an initial diagnosis has been made, IBS-C patients were only coded for IBS in the claims and no separate code for constipation was listed), then the exclusion of such patients should not affect our estimates. Also, our failure to capture patients who were misdiagnosed or undertreated may result in our results being an underestimate of the true incremental costs of IBS-C to the extent that such patients consume more resources related to specialist office visits and diagnostic tests and procedures. knowledge, no claims algorithm validation studies have been conducted for IBS-C. Exploratory analyses were conducted to better identify IBS-C patients in this study and mitigate misclassification. However, classification of IBS-C patients required assumptions based on available diagnostic codes and pharmacy prescriptions, leading to potential classification bias that may have affected the cost estimates. Further research should be undertaken to validate the identification of IBS-C patients in claims through a medical chart review. Furthermore, patients with IBS-C included in the study database were commercially insured, thereby limiting the generalizability of this study's findings to other populations, such as uninsured individuals or Medicaid recipients. Future studies should examine the economic burden of IBS-C in other patient populations. It should also be noted that this study does not provide prevalence estimates that are consistent with other population-based epidemiology studies of IBS-C. [4] [5] [6] Since this study aimed to quantify the economic burden of IBS-C among commercially insured patients identified through administrative claims, prevalence estimates generated from this study are substantially underestimated, likely due to undercoding of IBS or constipation diagnoses in claims data. Additionally, strict inclusion and exclusion criteria were applied in this study to increase specificity for identification of IBS-C patients in an effort to more accurately identify costs associated with IBS-C, Study concept and design were contributed by all authors. Data analysis was performed by Cai, with assistance from Doshi and Stephenson. All authors participated in data interpretation and manuscript development, review, and revision.
Authors
While this study attempted to be comprehensive in terms of matching patients on demographics and health plan type and controlling for ECI score and 15 other general and GI-related comorbidities, it is possible that our incremental cost estimates may have still been affected by residual confounding of unmeasured variables given the large differences observed in the presence of some comorbidities among IBS-C patients and controls. While the causal order is not established in the literature, to the extent that IBS-C affects the risk, persistence, or severity of comorbidities, such as depression or anxiety, the costs associated with these comorbidities may be considered long-term indirect effects associated with IBS-C and thus appropriately considered costs of patients with IBS-C. Accordingly, our approach of controlling for such conditions may have resulted in an underestimate of the true costs associated with IBS-C. The previously mentioned issues of undercoding in claims data as well as the influence of IBS-C on the persistence and severity of comorbidities may explain our finding of a large proportion of all-cause incremental costs in our study being non−IBS-C-related.
Finally, the results of this study may also underestimate the burden of IBS-C given that cost estimates only accounted for direct health care costs for services reimbursed by commercial insurers. Indirect costs were not included because relevant data cannot be captured from administrative claims. However, reduced productivity may also have a substantial economic impact on IBS-C patients and employers and should be assessed further. 13 Direct cost estimates in this study could also be underestimated due to a lack of data on over-the-counter medications or complementary/alternative medicines commonly used by IBS-C patients to self-treat their symptoms, which are often outside of health insurance coverage and not captured in administrative claims data. Furthermore, costs for patients aged 65 years and older could be underestimated because costs paid by other payers (e.g., coordination of benefits) for this population were not included in this study. The overall implications of these various caveats on the directionality of our estimates are unknown.
■■ Conclusions
Patients with IBS-C incur significantly higher direct health care costs compared with matched controls, even after controlling for general and GI-related comorbidities. The majority of incremental all-cause costs are attributable to a greater use of medical services. IBS-C-related costs were mainly driven by a greater use of physician office visits and other outpatient services. Further research should focus on the underlying factors driving increased medical resource use among IBS-C patients.
